What Is a Multi Dose Vial? Definition and What Research Reports

Plain definition

A multi dose vial (often written multi-dose vial, or abbreviated MDV) is a small sealed glass or plastic container of an injectable product that is designed so more than one amount can be withdrawn from it over time. A needle passes through a rubber stopper, an amount of liquid is drawn out, and the stopper reseals itself so the rest of the contents stays enclosed. The alternative is a single-dose vial, which is intended to be entered once and then discarded, even if liquid remains. The practical difference is not the size of the vial but the manufacturer's labelling and, in most licensed products, whether an antimicrobial preservative has been added to limit microbial growth after the first entry.

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified clinician for any question about medicines, injections or personal health. Nothing here describes how any product should be handled or used.

What a multi-dose vial is in technical and regulatory terms

In pharmaceutical terms, a multi-dose vial is a parenteral container qualified by its manufacturer for repeated puncture. That qualification rests on several documented properties: the elastomeric closure must reseal after repeated needle penetration without shedding particles (a phenomenon called coring); the formulation must pass antimicrobial effectiveness testing if a preservative is present; and the product must remain chemically stable across the labelled in-use period.

Preservatives

Common preservatives in licensed multi-dose injectables include benzyl alcohol, metacresol, phenol and thiomersal. Their function is bacteriostatic — they inhibit the growth of organisms that might be introduced during needle entry — rather than sterilising the contents. A vial without a preservative is not converted into a multi-dose vial by being large, by being refrigerated, or by being entered carefully. The distinction is a labelling and formulation fact, not a user decision.

Beyond-use dating and labelling

Licensed multi-dose products carry an in-use period defined by the manufacturer or by compounding standards, counted from first puncture rather than from the printed expiry date. Compounded and diluted preparations placed into multi-dose containers fall under separate pharmacy compounding rules, which is why several of the studies summarised below set out to measure sterility and potency of diluted drugs held in multi-dose vials for extended periods.

Research-use-only vials

Many peptide vials sold for laboratory work are labelled research use only (RUO) and are not approved medicines. RUO vials typically contain lyophilised (freeze-dried) powder with no preservative, no antimicrobial effectiveness data and no manufacturer-defined in-use period. Regulatory frameworks for multi-dose labelling apply to licensed drug products; an RUO vial has no such designation regardless of how many withdrawals a laboratory protocol involves.

How the term is used in peptide research — and where it is misused

In peptide literature and laboratory documentation, "multi-dose vial" is generally used in its narrow sense: a qualified container from which repeated withdrawals are anticipated, as in the veterinary and clinical studies cited on this page. Ambiguity appears in three places.

• Confusing volume with designation. A 10 mL vial is not automatically multi-dose; a 2 mL vial is not automatically single-dose. The designation comes from the label and the formulation.
• Confusing the diluent with the vial. Bacteriostatic water contains benzyl alcohol, while sterile water does not. Online peptide discussion frequently treats reconstitution with a bacteriostatic diluent as if it converted an unpreserved lyophilised vial into a licensed multi-dose product. That equivalence is not supported by any regulatory definition, and the published stability work cited below tested specific named drugs under specific storage conditions rather than peptides in general.
• Extrapolating sterility findings across products. Sterility results reported for one diluted drug in one setting are product-specific. They describe what researchers measured, not a general property of multi-dose containers.

Related terms

What the published literature reports

Sterility and stability over extended in-use periods

Several laboratory-animal studies examined whether diluted drugs stored in multi-dose vials remained sterile and potent. One 2019 study assessed diluted meloxicam in a compounded multi-dose vial and reported on sterility and stability after 365 days, as described in the study's published report. An earlier 2017 investigation applied a similar design to diluted carprofen in a multidose vial in the laboratory animal setting, and researchers reported sterility and stability outcomes for that preparation in the published paper. A 2023 veterinary study examined refrigerated multi-dose insulin vials and reported that the vials remained sterile through six months of use, as summarised in that report. Each of these findings applies to the specific drug, dilution and storage conditions tested.

Stability of the molecule itself is a separate question from sterility. Analytical work on the approved monoclonal antibody ramucirumab used a validated size-exclusion HPLC method to evaluate degradation patterns, illustrating how researchers characterise aggregation and breakdown of large biologics in solution (the published method paper).

Vaccine programmes, wastage and cost

Much of the published literature on multi-dose vials comes from immunisation programmes, where vial size determines how much product is discarded when a session has few attendees. A World Health Organization bulletin paper compared single-dose and multi-dose vaccine vials for immunisation programmes in developing countries (2003 analysis), and a 2010 Vaccine article examined immunisation and multi-dose vials more broadly (that paper). A 2021 report described vaccine wastage and cost saving after multi-dose vial policy implementation in Egypt (the published account), and a 2022 review set out perspectives from lower-middle income countries on multi-dose versus single-dose vials (that review). Related cost work outside vaccination examined dose rounding of biologic and cytotoxic antineoplastics as a source of cost avoidance (2017 study).

Vial tracking and documentation

Because a multi-dose vial is entered repeatedly, accounting for its contents is harder than for a single-dose container. A 2024 veterinary study compared three multidose vial tracking methods for accuracy and precision in the context of controlled drug tracking in practice (the published comparison).

Contamination, safe-practice and medication-error findings: What Studies Report

Multi-dose vials appear in the infection-prevention literature because repeated entry creates opportunities for contamination. A 2023 quality improvement initiative at a tertiary care centre assessed safe injection, infusion and medication-vial practices and reported on adherence to those practices, as documented in the published initiative. Broader nursing research on patient safety during medication administration has examined error and safety factors in that process (2018 study). These papers describe institutional settings with trained staff, documented protocols and audit systems; researchers did not study unsupervised handling, and the findings should not be read as generalisable beyond the contexts examined.

Limitations of the evidence

1. Most published multi-dose vial research concerns vaccines, veterinary analgesics, insulin or hospital practice — not peptides sold for research use.
2. Sterility findings are drug-, dilution- and storage-specific, and the studies above reported results only for the preparations they tested.
3. Cost and wastage results from immunisation programmes reflect programme logistics rather than any property of an individual vial.
4. No study in this set evaluated unlicensed or research-use-only peptide vials.

References

• Immunisation and multi-dose vials (Vaccine, 2010)
• Sterility and Stability of Diluted Meloxicam in Compounded Multi-dose Vial after 365 Days (JAALAS, 2019)
• Multi-dose vials versus single-dose vials for vaccination: perspectives from lower-middle income countries (Human Vaccines & Immunotherapeutics, 2022)
• Sterility and Stability of Diluted Carprofen in a Multidose Vial in the Laboratory Animal Setting (JAALAS, 2017)
• Cost avoidance from dose rounding biologic and cytotoxic antineoplastics (Journal of Oncology Pharmacy Practice, 2017)
• Refrigerated multi-dose insulin vials remain sterile through 6 months of use (Journal of Small Animal Practice, 2023)
• Accuracy and precision of 3 multidose vial tracking methods to inform controlled drug tracking in practice (American Journal of Veterinary Research, 2024)
• Safe injection, infusion and medication-vial practices at a tertiary care centre: a quality improvement initiative (GMS Hygiene and Infection Control, 2023)
• Vaccine wastage and cost saving after multi-dose vial policy implementation in Egypt: A success story (Vaccine, 2021)
• Patient safety in nursing care during medication administration (Revista Latino-Americana de Enfermagem, 2018)
• Stability assessment of FDA-approved ramucirumab monoclonal antibody; validated SE-HPLC method for degradation pattern evaluation (Biomedical Chromatography, 2022)
• Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries (Bulletin of the World Health Organization, 2003)